Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Atlanta, Georgia


This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.


Inclusion Criteria: - Major Depressive Disorder - Current episode of major depression that has not benefited from at least 1 but no more than 3 adequate treatment regimens - Has as score of >/= 18 on the Ham-D-17 Exclusion Criteria: - Pregnant or breast-feeding women - Evidence of age-related cognitive decline or mild dementia - At imminent risk of committing suicide - Has with the exception of major depression, a serious medical or neurological illness, including seizure disorder, stroke, dementia, or Parkinson disease - Has an established diagnosis of bipolar disorder, hypomania, schizoaffective disorder, major depression with psychotic features or schizophrenia - Has had a substance or alcohol abuse or dependence disorder (except nicotine and caffeine) in the 1 year before screening



Primary Contact:

Study Director
Doris Greiling, PhD
Evotec AG

Backup Contact:


Location Contact:

Atlanta, Georgia
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.